Cover of: Ifosfamide in the treatment of lung cancer |

Ifosfamide in the treatment of lung cancer

satellite symposium of the 19th German Cancer Congress, Frankfurt/Main, February 28, 1988
  • 153 Pages
  • 1.91 MB
  • English

Karger , Basel, New York
Lungs -- Cancer -- Chemotherapy -- Congr
Statementvolume editor, D.K. Hossfeld.
SeriesContributions to oncology ;, vol. 35 =, Beiträge zur Onkologie, Contributions to oncology ;, vol. 35.
ContributionsHossfeld, D. K., Deutscher Krebskongress (19th : 1988 : Frankfurt am Main, Germany)
LC ClassificationsRC280.L8 I36 1989
The Physical Object
Paginationvi, 153 p. :
ID Numbers
Open LibraryOL1967247M
ISBN 103805551991
LC Control Number90202043

Ifosfamide in the Treatment of Lung Cancer: Satellite Symposium of the 19th German Cancer Congress, Frankfurt/Main, February (Contributions to Oncology, Vol. 35): Medicine & Health Science Books @ The search identi fied trials comparing ifosfamide + etoposide + platinum to etoposide + platinum in the treatment of small-cell lung cancer.

Data extraction The same investigators (H.Z.Y. and Y.M.) independently extracted relevant data on study characteristics and examination results by using a standardized by: 2. The combination of ifosfamide and docetaxel in the treatment of non-small cell lung cancer (NSCLC) resulted in three (6%) Ifosfamide in the treatment of lung cancer book developing interstitial pneumonitis, two of whom died, suggesting a synergistic effect between the two (Chen et al.

The oxazaphosphorine cytostatic ifosfamide (IFO) has been successfully integrated in the treatment of various hematological and solid tumors. The purpose of this review is to summarize the evidence for its use in lung cancer starting from basic data of preclinical studies followed by a global summary of the phase III and seminal phase II clinical by: 1.

FDA label information for this drug is available at DailyMed. Use in Cancer. Ifosfamide is approved to be used with other drugs to treat.

Testicular germ cell tumors that are is used in patients who have already been treated with two other types of chemotherapy.; Ifosfamide is also being studied in the treatment of other types of cancer.

Epirubicin has shown clinical activity at doses ranging from 75 to mg/m 2 in the treatment of SCLC. In a non-small cell lung cancer population, the combination of ifosfamide and epirubicin has been investigated at the doses of g/m 2 and 70 mg/m 2 respectively, every 4 weeks with a favorable toxicity profile.

This study was conducted to compare the efficacy and safety of ifosfamide plus etoposide plus platinum (IEP) to that of etoposide plus platinum (EP) in patients with previously untreated small‑cell lung cancer. 62 Zhou and Manegold. The role of ifosfamide in lung cancer Translational lung cancer research.

ll rights resered. Transl ung Cancer Res Small cell lung cancer: the Western evidence A randomized study of chemotherapy-naive patients with extensive disease SCLC compared IFO or teniposide given. Most often associated with treatment of Small Cell Lung Cancer.

Ifosfamide (Ifex®) Ifosfamide is an anti-cancer ("antineoplastic" or "cytotoxic") chemotherapy drug.

Download Ifosfamide in the treatment of lung cancer PDF

This medication is classified as an "alkylating agent." Ifosfamide is give through an infusion into a vein (intravenous, IV). Ifosfamide is one of the most active systemic agents for the treatment of patients with sarcoma. In addition to its anticancer activity, ifosfamide is a radiosensitizing agent.

5, 6 When human cell lines, including squamous cell carcinoma, colon carcinoma, melanoma, and nonsmall cell lung carcinoma lines, are exposed to radiation in combination with ifosfamide or its derivative, 4.

Ifosfamide at 5 g/m2 was given as a bolus to 48 patients with advanced progressing non-small cell lung cancer.

Mesna (5 g/m2) was also given with the ifosfamide, both over 30 min. Further mesna was then given p.o. (3 g/m2) at 4, 8, and 12 h. Gemcitabine, ifosfamide, cisplatin (GIP) for the treatment of advanced non‐small cell lung cancer: A phase II study of the Italian oncology group for clinical research (goirc) C.

Boni. Corresponding Author. E-mail address: [email protected] Costanzi JJ, Morgan LR, Hokanson J () Ifosfamide in the treatment of extensive non-oat cell carcinoma of the lung. Semin Oncol 9: 61 Google Scholar. Cullen MH, Joshi R, Chetiyawardana A, Woodroffe CM () Mitomycin, ifosfamide and cisplatin in non-small cell lung cancer: treatment good enough to compare.

Drink plenty of liquids while you are taking ifosfamide. Your blood will need to be tested often. Your heart, kidney function, liver function, or nerve and muscle function may also need to be checked. Your cancer treatments may be delayed based on the results. Ifosfamide can have long lasting effects on.

Non-small cell and small cell lung cancer ; Bladder cancer ; Head and neck cancer ; Cervix cancer; Note: If a drug has been approved for one use, physicians may elect to use this same drug for other problems if they believe it may be helpful. How Ifosfamide Is Given: Ifosfamide is give through an infusion into a vein (intravenous, IV).

Description Ifosfamide in the treatment of lung cancer EPUB

Part of the Chemotherapy book series (CT, volume 8) Abstract This study carried out by 24 authors and more than a dozen hospitals resulted in the abandonment of Ifosfamide (substance Z) for clinical use because it was found to be inferior compared with Endoxan.

Treatment. The neoadjuvant chemotherapy regimen investigated included 75 mg/m 2 etoposide per day administered via a 90‐minute infusion on Days 1–5, mg/m 2 ifosfamide per day administered via a 1‐hour infusion with sodium mercaptoethanesulfonate (mesna) on Days 1–5, and 20 mg/m 2 cisplatin per day administered (together with adequate hydration) via a 15‐minute infusion on.

provides accurate and independent information on more t prescription drugs, over-the-counter medicines and natural products. This material is provided for educational purposes only and is not intended for medical advice, diagnosis or treatment. Data sources include IBM Watson Micromedex (updated 2 Nov ), Cerner Multum™ (updated 2 Nov ).

The authors evaluated the efficacy and toxicity of the combination of carboplatin, ifosfamide, and vinorelbine in the treatment of advanced non-small-cell lung cancer. From March through March56 previously untreated patients with stage IIIB or stage IV non-small-cell lung cancer with measurable lesions and good performance status.

There is no standard treatment recommendation for this group of patients who failed to second-line therapy and had good performance status. Some cytotoxic drugs for the treatment of non-small cell lung cancer, i.e.

vinorelbine, paclitaxel, and ifosfamide, were used in. Ifosfamide in the treatment of lung cancer. Basel ; New York: Karger, © (OCoLC) Online version: Ifosfamide in the treatment of lung cancer. Basel ; New York: Karger, © (OCoLC) Material Type: Conference publication: Document Type: Book: All Authors / Contributors: D K Hossfeld.

Adenocarcinoma is now the most common type of lung cancer; squamous cell carcinoma and small cell lung cancer (SCLC) have decreased during the past 20 years (1 – 3). SCLC accounted for 25% of all lung cancers in the United States in the s but only % in (2, 4). The number of patients who are diagnosed with lung.

The results of this study are noteworthy in that,in previous studies, the mitomycin, ifosfamide, and cisplatin regimen was shownto be superior to supportive care and doublet study provides further support of the benefit of gemcitabine/cisplatin inthe treatment of non-small-cell lung cancer.

Details Ifosfamide in the treatment of lung cancer EPUB

Gemcitabine and Cisplatin Versus Mitomycin, Ifosfamide, and Cisplatin in Advanced Non–Small-Cell Lung Cancer: A Randomized Phase III Study of the Italian Lung Cancer Project Article Nov Clinical trials are research studies that involve people.

The clinical trials on this list are studying Ifosfamide. All trials on the list are supported by NCI. NCI’s basic information about clinical trials explains the types and phases of trials and how they are carried out.

Clinical trials look at new ways to prevent, detect, or treat disease. Ifosfamide is also sometimes used to treat bladder cancer, lung cancer, cancer of the ovaries (cancer that begins in the female reproductive organs where eggs are formed), cancer of the cervix, and certain types of soft tissue or bone sarcomas (cancer that forms in muscles and bones).

In recent years the role of chemotherapy in advanced non-small cell lung cancer (NSCLC) has been well established. Ifosfamide is an old drug still considered an effective cytostatic agent in the treatment of NSCLC. As a single agent, it has showed a response rate of %.

Ifosfamide is also sometimes used to treat bladder cancer, lung cancer, cancer of the ovaries (cancer that begins in the female reproductive organs where eggs are formed), cancer of the cervix, and certain types of soft tissue or bone sarcomas (cancer that forms in muscles and bones).

Lung cancer has long been the number-one cause of death from cancer every year and the third most frequently diagnosed after breast and prostate cancers. Inabout 15% of all cancer diagnoses and 30% of all cancer deaths were due to lung cancer.

In view of epirubicin combined with ifosfamide (EI) scheme is effective and safety in the treatment of refractory and relapsed SCLC, the investigators will use liposomal doxorubicin plus ifosfamide second-line treatment of refractory and relapsed small cell lung cancer, may obtain better tumor remission rate, improve the prognosis of the patients.

We conducted a phase II study of ifosfamide and etoposide chemotherapy in patients with untreated extensive-disease small-cell lung cancer to assess response and toxicity.

Between January and December16 patients were treated.Ifosfamide, like cyclophosphamide, is an oxazophosphorine alkylating agent. Following activation in the liver, ifosfamide interferes with DNA through formation of phosphotriesters and DNA-DNA crosslinks, thereby inhibiting protein synthesis and DNA synthesis.1,4 Ifosfamide is cell cycle-specific, but cell cycle phase non-specific.1,4.T1 - The role of ifosfamide in small cell lung cancer.

AU - Loehrer, Sr. PY - /8/ Y1 - /8/ N2 - The emergence of chemotherapy has dramatically improved both quality of life and survival in patients with small cell lung cancer (SCLC).

Nonetheless, achieving long-term survival in SCLC patients has been a problem.